|View printer-friendly version|
|Overall Survival Benefit with VELCADE® based Therapy in Previously Untreated Multiple Myeloma Patients Maintained after Five Year Follow-Up|
− Additional study shows VELCADE based maintenance nearly doubles complete response rate following VELCADE based induction −
SAN DIEGO, Calif., December 12, 2011 - Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today reported results from the final five-year follow-up analysis of the international, multicenter, Phase III VISTA1 trial. The analysis assessed overall survival (OS) after treatment with VELCADE (bortezomib) in combination with melphalan and prednisone (VcMP) versus melphalan and prednisone (MP) alone, in patients with previously untreated multiple myeloma (MM) at a median follow-up of 60.1 months. The data were presented by Professor Jesús F. San Miguel, M.D., Ph.D., Hospital Clìnico Universitario de Salamanca, Salamanca, Spain, during an oral session at the 53rd annual meeting of the American Society of Hematology (ASH), held December 10-13, 2011 in San Diego, California. These long-term OS data were also the basis of the recent FDA-approved label update for VELCADE.
“This VELCADE-based therapy resulted in an impressive 13.3-month increase in the median overall survival after five years of follow-up,” said San Miguel. “These data confirm that starting previously untreated multiple myeloma patients with the VELCADE based combination (VcMP) provided a significant survival advantage over MP, a recognized standard of care, that could not be regained despite the substantial use of novel agent based salvage therapies including VELCADE.”
The VISTA trial was conducted in 682 previously untreated MM patients ineligible for high-dose therapy, and compared VcMP versus MP treatment alone. The primary endpoint of the study was time-to-disease progression, and secondary end points for the study were: OS, progression free survival (PFS), response rates and safety. After a median follow-up of 60.1 months, median OS was 56.4 versus 43.1 months for patients randomized to VcMP and MP, respectively - a significant survival advantage of 13.3 months for the VcMP arm (p=0.0004). An exploratory analysis of the incidence rate of secondary primary malignancies (SPM) reported an exposure-adjusted incidence rate of 1.66 SPM per 100-patient-years for VcMP, and 1.30 SPM for MP alone.
“Elderly patients with multiple myeloma strive for upfront therapy that will extend their lives,” said Karen Ferrante, M.D., Chief Medical Officer, Millennium. “Today's VELCADE data confirmed the sustained clinical benefits, including overall survival and complete response, that VELCADE provided in patients with previously untreated MM.”
Continued Overall Survival Benefit After 5 Years' Follow-Up with Bortezomib-Melphalan-Prednisone (VcMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial (Abstract #476)
The updated results showed:
Patients were randomized (1:1) to receive nine 6-week cycles of VcMP (N=344; bortezomib 1.3 mg/m2, days 1, 4, 8, 11, 22, 25, 29, and 32, cycles 1 - 4, days 1, 8, 22, and 29, cycles 5 - 9; melphalan 9 mg/m2 days 1 - 4, prednisone 60 mg/m2, days 1 - 4, all cycles) or MP (N=338) alone. Patients were followed at least every 12 weeks for survival and subsequent therapy use. Data on SPM were collected by surveying all study sites to capture information for 655 (96 percent) patients.
Maintenance therapy with bortezomib plus thalidomide (VT) or bortezomib plus prednisone (VP) after induction with bortezomib, melphalan and prednisone (VcMP) or bortezomib, thalidomide and prednisone (VTP) in elderly untreated myeloma patients included in the GEM2005MAS65 Spanish randomized trial. (Abstract #477)
This Phase III trial in 260 elderly patients, with a median age of 73 years, was conducted by the Spanish Myeloma Group PETHEMA/GEM. The patients remained on maintenance therapy for up to three years. One third of the patients were over the age of 75. The updated results, presented by María-Victoria Mateos, M.D., Hospital Universitario de Salamanca, Salamanca, Spainshowed:
Patients were randomized to receive six cycles of VMP or VTP as induction therapy followed by randomization to maintenance. Maintenance therapy included VELCADE 1.3 mg/m2 on day 1, 4, 8, 11 every three months for both arms, plus either thalidomide 50 mg daily for VT or prednisone 50 mg every other day for VP for up to three years.
VELCADE® (bortezomib) is approved for the treatment of patients with multiple myeloma. VELCADE is also approved for the treatment of patients with mantle cell lymphoma who have already received at least one prior treatment.
Patients should not receive VELCADE if they are allergic to bortezomib, boron or mannitol. Women should be advised not to take VELCADE while pregnant or breast-feeding. Patients with diabetes may require close monitoring and adjustment of their medication.
VELCADE can cause serious side effects, including:
Common side effects seen in patients receiving VELCADE include: fever, decreased appetite, fatigue, insomnia and headache.
Additional information and full prescribing information is available at www.VELCADE.com.
For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).
Editor's Note: This press release is also available under the Media section of the Company's website at: www.millennium.com/InTheNews.aspx.
1(VELCADE as Initial Standard Therapy in Multiple Myeloma)